{"schema_version":"secwatch.filing_event.v1","accession":"0001295947-22-000030","form_type":"8-K","ticker":"PBH","cik":"0001295947","company_name":"Prestige Consumer Healthcare Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.042199+00:00","generated_at":"2026-06-22T08:15:21.112142+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prestige Q2 revenue $289.3M (+4.7% YoY), EPS $1.02; reaffirms FY2023 outlook","bullets":["Record Q2 revenue $289.3M (+4.7% YoY, +5.5% ex-currency); diluted EPS $1.02, ahead of expectations.","International OTC segment revenue $37.2M (+51.9% YoY) driven by Hydralyte demand.","Reduced debt by $35M; leverage ratio 3.7x; completed $50M share repurchase program.","Reaffirms FY2023 outlook: revenue $1.12-1.13B, diluted EPS $4.18-4.23, FCF $260M+."],"urls":{"canonical":"https://secwatch.observer/filing/0001295947-22-000030","json":"https://secwatch.observer/filing/0001295947-22-000030.json","markdown":"https://secwatch.observer/filing/0001295947-22-000030.md","text":"https://secwatch.observer/filing/0001295947-22-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1295947/000129594722000030/0001295947-22-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1295947/000129594722000030/pbh-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:15:21.112142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"201fa495300ea1576127bb1c7bdb03748dd7a15f","claim":"Prestige Consumer Healthcare Inc. reported the fiscal quarter and six months ended September 30, 2022 results: revenue $289.3 million, net income $51.0 million, EPS $1.02. Guidance reaffirmed.","evidence_excerpt":"herein by reference. --- EX-99.1 (EX-99.1) --- Prestige Consumer Healthcare Inc. Reports Second Quarter Results and Reaffirms Outlook for Fiscal 2023 ◦ Record Revenue of $289.3 Million in Q2 fiscal 2023 increased 4.7% versus Prior Year and 5.5% excluding Currency ◦ Diluted EPS of $1.02 for Q2, ahead of expectations ◦ Reduced Debt by $35 million in Q2 and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1295947/000129594722000030/0001295947-22-000030-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter and six months ended September 30, 2022"},{"label":"Revenue","value":"$289.3 million"},{"label":"Net income","value":"$51.0 million"},{"label":"EPS","value":"$1.02"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}